

Larry Howard Danziger, Pharm.D.
University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Practice
833 South Wood Street (M/C 886)
Chicago, IL 60612
312-996-0892 (Phone)
312-413-1797 (Fax)
danziger@uic.edu (Email)

Professional Experience

4/2010 to Present	Professor of Pharmacy in Medicine Department of Medicine College of Medicine University of Illinois at Chicago
2/2010 – Present	Executive Director Center for Advanced Design, Research and Exploration (CADRE) University of Illinois at Chicago
7/95 - Present	Professor of Pharmacy Practice Co-Director, Section of Infectious Diseases Pharmacotherapy University of Illinois at Chicago
01/08-2/2010	Interim Vice Chancellor for Research University of Illinois at Chicago
12/08 - 2/09	Interim Director Center for Advanced Design, Research and Exploration (CADRE) University of Illinois at Chicago
10/99-01/08	Associate Vice Chancellor for Research University of Illinois at Chicago
9/05 – 6/2009	Human Protections Administrator Office of the Vice Chancellor for Research University of Illinois at Chicago
7/90 to 7/95	Associate Professor of Pharmacy Practice University of Illinois at Chicago
8/85 to 7/90	Assistant Professor of Pharmacy Practice Department of Pharmacy Practice College of Pharmacy University of Illinois at Chicago
7/90 to 4/2010	Assistant Professor of Pharmacy in Medicine Department of Medicine College of Medicine

	University of Illinois at Chicago
9/80 – 8/85	Adjunct Clinical Assistant Professor Department of Pharmacy Practice College of Pharmacy The University of Toledo Toledo, Ohio
8/78 to 8/85	Clinical Pharmacist in Surgery University Hospitals of Cleveland Clinical Instructor in Surgery Department of Surgery School of Medicine CaseWestern ReserveUniversity Cleveland, Ohio
7/76 to 7/78	Pharmacist Resident VeteransAdministrationCincinnatiMedicalCenter Cincinnati, Ohio
7/75 to 6/76	Pharmacy Apprentice Westridge Pharmacy Chicago, Illinois
6/74 to 6/75	Pharmacy Apprentice EvanstonHospital Evanston, Illinois

Education

1976 to 1978	University of Cincinnati College of Pharmacy Doctor of Pharmacy Degree Conferred June 1978
1973 to 1976	University of Illinois at Chicago College of Pharmacy Bachelor of Science in Pharmacy Degree conferred June 1976
1969 to 1973	University of Illinois at Urbana-Champaign College of Liberal Arts and Sciences Bachelor of Arts in History Degree conferred June 1973

Professional License

Illinois

Professional Affiliations

- Alliance for the Prudent Use of Antibiotics (APUA)
- American Association of Colleges of Pharmacy (AACCP)
- American College of Clinical Pharmacy (Elected) (ACCP)
- The American Society for Microbiology (ASM)
- American Society of Health-System Pharmacists (ASHP)
- Surgical Infection Society (Elected) (SIS)
- Infectious Diseases Society of America (Elected) (IDSA)
- Illinois Council of Health-System Pharmacists (IChP)
- Illinois Pharmacists Association (IPhA)

Awards/Honors

- | | |
|------|---|
| 2010 | Researcher of the Year Award, University of Illinois at Chicago (Honorary) |
| 2004 | Fellow, Infectious Diseases Society of America (Elected) |
| 2002 | Fellow, Committee on Institutional Cooperation Academic Leadership Program (CIC ALP) |
| 1999 | Society of Infectious Diseases Pharmacists Research Award |
| 1998 | Certificate of Appreciation P-4 Class
University of Illinois at Chicago, College of Pharmacy |
| 1994 | Office of Technology Management Development Award
University of Illinois at Chicago |
| 1994 | Elected Phi Lambda Sigma - Pharmacy Leadership and Honor Society |
| 1994 | Robert Wood Johnson Visiting Professorship
Mary Imogene Bassett Hospital |
| 1991 | Certificate of Appreciation
American Society for Parenteral and Enteral Nutrition |
| 1991 | 1st Annual Pharmacoeconomics Award
American College of Clinical Pharmacy |
| 1990 | Campus Research Board (CRB) – Small Equipment Award
University of Illinois at Chicago |
| 1976 | Bristol Award, College of Pharmacy
University of Illinois at Chicago |

Professional Activities**Editor**

- 1992 – 1996 Pharmacotherapy Self Assessment Program I and II; Diseases of the Gastrointestinal Tract: Module IV, American College of Clinical Pharmacy
- 1998 – 2000 Clinical Trends Newsletter

Editorial Board

- 1990 – 1992 Task Force on Antimicrobial Prophylaxis in Surgery
American Society of Hospital Pharmacists
- 1995 – Present Diagnostic Microbiology and Infectious Diseases
- 1995 – 1998 Surgical Therapeutics: Annals of Pharmacotherapy DICP
- 1995 – 2006 Pharmacotherapy
- 1997 – 1999 Infectious Diseases: Pharmacoeconomics Newsletter
- 1997 -1999 Task Force on Surgical Antimicrobial Prophylaxis
American Society of Hospital Pharmacists
- 1997 – 1999 Task Force on Non-Surgical Antimicrobial Prophylaxis
American Society of Hospital Pharmacists
- 2000 – 2004 Journal of Infectious Diseases Pharmacotherapy

Ad hoc Reviewer

- 1994 – 1996 American Hospital Formulary Service (1994 – 1996)
- 1989 – Present American Journal of Health-System Pharmacy
- 1989 – Present Annals of Pharmacotherapy
- 1992 – Present Antimicrobial Agents and Chemotherapy
- 2000 – Present Journal of Infectious Control and Hospital Epidemiology
- 1992 – Present Pharmacotherapy
- 1997 – Present Phytopharmacology
- 1990 – Present Diagnostic Microbiology and Infectious Diseases
- 2008 – Present Expert Opinion on Drug Metabolism and Toxicology

Committee Memberships (External)

- 1985 – 1987 American Society for Parental and Enteral Nutrition (ASPEN)

	Annual Meeting Planning Committee
1990 – 1994	Michael Reese Hospital and Medical Center Antibiotic SubCommittee of the Pharmacy and Therapeutics Committee
1996 - 2000	American College of Clinical Pharmacy Grant and Abstract Review Committee
1996 – 1997	American Society of Hospital Pharmacists Foundation Fellowship and Grant Review Committee
2000 – 2002	Society of Infectious Diseases Pharmacists Awards Committee
2002 – 2003	Walgreens National Advisory Board
2003 – 2005	Walgreens Health Initiative (WHI) Ethics Committee
2004 – 2005	American College of Clinical Pharmacy Abstract Review Committee
2004 – 2005	National Health and Medical Research Council (NHMRC), Australia Grant Reveiwer
2005 – 2007	Council for Appropriate and Rational Antibiotic Therapy (CARAT)
2007 – Present	Illinois Council of Health Care Professionals Education Committee
2008 – 2010	Illinois Ventures Board of Directors
2008 – 2010	Argonne National Laboratory Board of Governors (Ex-Officio)
2008 – 2010	Argonne National Laboratory Science Policy Council

Committee Member (University of Illinois)

1988 – 1989	College of Pharmacy - Discipline Committee
1988 - 1990	University of Illinois at Chicago Faculty Senate
1989 - 2000	College of Pharmacy- Educational Policy Committee, Chair; Curriculum Committee, Chair
1989 – Present	University of Illinois Hospital & Health Sciences System– Antibiotic SubCommittee, Pharmacy and Therapuetics Committee
1991 -1993	College of Pharmacy - International CCO Program

1990 -1993	Ad Hoc Committee, Health Summit Council Austin Community Office of the Vice Chancellor for Health Affairs
1990 – Present	College of Pharmacy - Continuing Education Advisory Committee
1990 – 1992	University of Illinois at Chicago - HIV/AIDS Policy Guideline Committee
1994 – 1999	University of Illinois at Chicago - Institutional Review Board, Chair
1995 – 1997	College of Pharmacy - Infrastructure Subcommittee
1996 – 1998	College of Pharmacy - Strategic Planning Committee
1999 – 2000	University of Illinois at Chicago - Search Committee for the Director position, Institute for Tuberculosis Research
1999 – 2000	College of Pharmacy - Laboratory Utilization Subcommittee
1999 – 2000	University of Illinois at Chicago – Office of the Vice Chancellor for Research, Human Subjects Protections Steering Committee
1999 – 2000	University of Illinois at Chicago - Human Subjects Allowance Committee, Chair
2002 -2004	College of Pharmacy - Executive Committee, Member Promotion and Tenure Committee, Chair
2003 - 2004	University of Illinois at Chicago - Ad Hoc Academic Administration Review Committee
2004 - 2005	University of Illinois at Chicago - HIPAA Committee
2004 - 2006	College of Pharmacy. Department of Pharmacy Practice - Advisory Committee
2005 – 2007	College of Pharmacy - Executive Committee, Member Promotion and Tenure Committee, Chair
2005 – 2006	University of Illinois at Chicago - NCA Re-Accreditation Committee
2005 – 2007	University of Illinois at Chicago - Time and Effort Analysis Committee
2006 - 2006	College of Pharmacy – Search Committee for the Dean of Pharmacy
2008 – 2010	College of Pharmacy - Executive Committee, Member Promotion and Tenure Committee, Chair
2006 – 2008	University of Illinois at Chicago - UIC/City of Chicago Contracts Budget Impass Oversight Committee
2008 – 2010	University of Illinois at Chicago – OBFS Research Advisory Committee , Co-Chair

2008 – 2010	Jessie Brown Veterans Administration Medical Center/UIC – Human Subjects Oversight Executive Committee
2008 – 2010	University of Illinois Research Park - Board of Managers
2008 – 2010	University of Illinois at Chicago - Health Science Council
2008 – 2010	University of Illinois - Academic Affairs Management Team (AAMT)
2010 – Present	Department of Pharmacy Practice Promotion and Tenure Committee, Chair
2011 – Present	Campus Promotion and Tenure Committee, University of Illinois at Chicago
2012 – Present	Member of Senate, University of Illinois at Chicago
2012 – 2012	IllinoisVENTURES, LLC. Evaluation Committee. Co-Chair

Publications:

Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, **Danziger LH**. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009, *J Antimicrob Chemother*. 2013 Mar;68(3):715-8.

Crawford T, Huesgen E, **Danziger L**, Fidaxomicin: a novel macrocyclic antibiotic for the treatment of *Clostridium difficile* infection. *Am J Health Syst Pharm*. 2012 Jun 1;69(11):933-43.

Colvard M, Naiman, M, **Danziger L**; Hanley L. Handheld Directed Energy Sensor for Environmental Monitoring and Clinician Safety. *Aviation Space and Environmental Medicine*. 2010;81:602-04.

Wieczorkiewicz SM, Jourjy J, **Danziger L**, An Update on the Pharmacoeconomics of Antifungal Pharmacotherapy. *Current Fungal Infection Reports*. 2009;3:103-110.

DePestel DD, Benninger MS, **Danziger L**, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. Cephalosporin use in treatment of patients with penicillin allergies. *J Am Pharm Assoc* (2003). 2008 Jul-Aug;48(4):530-40.

Jain R, Schriever CA, **Danziger LH**, Cho SH, Rubinstein I. The IS6110 repetitive DNA element of *Mycobacterium tuberculosis* is not detected in exhaled breath condensate of patients with active pulmonary tuberculosis. *Respiration*. 2007;74(3):329-33.

Joseph JM, Jain R, **Danziger LH**. Micafungin: a new echinocandin antifungal. *Pharmacotherapy*. 2007 Jan;27(1):53-67.

Slover CM, Rodvold KA, **Danziger LH**. Tigecycline: a novel broad-spectrum antimicrobial. *Ann Pharmacother*. 2007 Jun;41(6):965-72. Epub 2007 May 22.

Itokazu GS, Schwartz DN, Garey KW, Rodvold KA, **Danziger LH**, Weinstein RA. Pharmacists' perceptions of the effectiveness of antimicrobial control programs. *Am J Health Syst Pharm*. 2006 Dec 15;63(24):2504-8.

- Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, **Danziger LH**, Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. *Diagn Microbiol Infect Dis*. 2006 Aug;55(4):303-9.
- Johnson MD, Kleinberg M, **Danziger L**, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. *Expert Opin Pharmacother*. 2005 Dec;6(15):2617-32.
- Suda K J, Garey KW, **Danziger LH**. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolones. *Pharm World Sci*. 2005;27:81-82.
- Schriever CA, Fernandez C, Rodvold KA, **Danziger LH**. Daptomycin: A Novel Cyclic Lipopeptide Antimicrobial. *Am J Health Syst Pharm*. 2005 Jun 1;62(11):1145-58.
- Cannon JP, Lee TA, Bolanos JT, **Danziger LH**. Pathogenic relevance of *Lactobacillus*: a retrospective review of over 200 cases. *Eur J Clin Microbiol Infect Dis*. 2005 Jan;24(1):31-40.
- Lodise TP Jr, Lomaestro B, Rodvold K, **Danziger L**, Drusano G. Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. *Antimicrob Agents Chemother*. 2004 Dec;48(12):4718-724.
- Sprandel KA, Schriever CA, Pendland SL, Quinn JP, Gotfried MH, Hackett S, Graham MB, **Danziger LH**, Rodvold KA. Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects. *Antimicrob Agents Chemother*. 2004 Dec;48(12):4597-605.
- Jain R, **Danziger L**. Multidrug-resistant acinetobacter infections: an emerging challenge to clinicians. *Ann Pharmacother*. 2004 Sep;38(9):1449-1459.
- Jain R, **Danziger L**. The Macrolide Antibiotics: A Pharmacokinetic and Pharmacodynamic Overview. *Curr Pharmacol Design*. 2004;10(25):3045-53.
- Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, **Danziger LH**. Effects of Six-week Clarithromycin Therapy in Subjects with Corticosteroid-dependent Asthma. *Current Therapeutic Research*. 2004 Jan; 65(1):1-12.
- Garey KW, Neuhauser MM, Robbins RA, **Danziger LH**, Rubinstein I. Markers of Inflammation in Exhaled Breath Condensate of Young Healthy Smokers. *Chest*. 2004 Jan;125(1):22-26.
- Gunderson SM, Hayes R, Quinn J, **Danziger LH**. In Vitro Pharmacodynamic Activities of ABT-492, A Novel Quinolone, Compared to Those of Levofloxacin Against *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. *Antimicrob Agents Chemother*. 2004 Jan;48(1):203-208.
- Gunderson S, Rupali J, **Danziger L**. Voriconazole: A Novel Antifungal. *J Pharm Technol*. 2003 March/April;19(2):97-108.
- Graham JG, Pendland SL, Prause J, **Danziger L**, Fernando C, Farnsworth N. Antimycobacterial Evaluation of Peruvian Plants. *Phytomedicine*. 2003;10(6-7):528-535.

Rodvold K, **Danziger L**, Gotfried M. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. *Antimicrob Agents Chemother.* 2003 Aug;47(8):2450-2457.

Gotfried M, **Danziger L**, Rodvold K. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. *J Antimicrob Chemother.* 2003 Sep;52(3):450-456.

Cannon J, Fiscella R, Pattharachyakul S, Garey K, DeAlba F, Piscitelli S, **Danziger L**. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. *Invest Ophthalmol Vis Sci.* 2003 May;44(5):2112-2117.

Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, **Danziger L**, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. *Clin Infect Dis.* 2003 May 15;36(10):1221-1228. Epub 2003 May 08.

Rodvold K, **Danziger L**, Gotfried M. Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults. *Antimicrob Agents Chemother.* 2003;47:2450-2457.

Neuhauser M, Weinstein R, Rydman R, **Danziger L**, Karam G, Quinn J. Increasing Resistance to Fluoroquinolones Among Gram Negative Bacilli from Intensive Care Unit Patients. *JAMA.* 2003 Feb 19;289(7):885-888.

Neuhauser M, Prause J, **Danziger L**, Pendland S. In Vitro Bactericidal Activity of ABT 773 Against *ermB* Strains of *Streptococcus pneumoniae* *Antimicrob Agents Chemother.* 2003; 47:1132-1134.

Garey KW, Alwani A, **Danziger L**, Rubinstein I. Tissue Reparative Effects of Macrolide Antibiotics in Chronic Inflammatory Sinopulmonary Diseases. *Chest.* 2003;123:261-265.

Itokazu G, Fischer J, Manipisitkul P, Hariharan R, **Danziger L**. Lack of Effect of Nizatidine Induced Elevation of Gastric pH on the Oral Bioavailability of Dapsone in Healthy Volunteers. *Pharmacotherapy.* 2002;1420-1425.

Neuhauser M, Jung R, **Danziger L**, Pendland S. In Vitro Bactericidal Activity of ABT-773 versus Four Other Agents Against *Streptococcus Pneumoniae* and *Haemophilus influenzae*. *Int J Antimicrob Agents.* 2002;20(5):395-398.

Pai MP, **Danziger L**, Pendland SL. Management of Candidiasis in Critically Ill Patients. *J Pharm Pract.* 2002;15:106-113.

Jung R, **Danziger LH**, Pendland SL. Intracellular activity of ABT-773 and other antimicrobial agents against *Legionella pneumophila*. *J Antimicrob Chemother.* 2002 May;49(5):857-861.

Max B, Itokazu G, **Danziger L**, Weinstein R. Rapid Assessment of Discrepancies in a Unit Dose System. *Am J Health-Syst Pharm.* 2002;59:856-858.

Drusano G, Preston S, Gotfried M, **Danziger L**, Rodvold K. Levofloxacin Penetration into Epithelial

Lining Fluid as Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation. *Antimicrob Agents Chemother.* 2002;46:586-589.

Lesch CA, Itokazu GS, **Danziger L**, Weinstein R. Multi-hospital Analysis of Antimicrobial Usage and Resistance Trends. *Diagn Microbiol Infect Dis.* 2001 Nov;41(3):149-154.

Neuhauser M, Prause J, **Danziger L**, Pendland S. Postantibiotic effect of ABT 773 and Amoxicillin/Clavulanate against *Streptococcus pneumoniae* and *Haemophilus influenzae*. *Antimicrob Agents Chemother.* 2001;45:3613-3615.

Cannon J, Garey K, **Danziger L**. Prospective and Retrospective Analysis of Nephrotoxicity and Efficacy of Lipid Based Amphotericin B Formulations. *Pharmacotherapy.* 2001; 21:(9)1107-1114.

Rodvold K, Gotfried M, **Danziger L**. Steady State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects. *Chest.* 2001 Apr;119(4):1114-1122.

Mutlu G, Garey K, Robbins R, **Danziger L**, Rubinstein I. Collection and Analysis of Exhaled Breath Condensate in Humans. *Am J Resp Crit Care Med.* 2001 Sep 1;164(5):731-737.

Bearden D, **Danziger L**. Mechanism of Action of and Resistance to Quinolones. *Pharmacotherapy.* 2001 Oct; 21(10 Pt 2):224S-232S.

Pai M, Pendland S, **Danziger L**. Antimicrobial-Coated, Bonded and Impregnated Catheters. *Ann Pharmacother.* 2001 Oct; 35(10):1255-1263.

Rodvold K, Gotfried M, Garey K, **Danziger L**. Steady State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects. *Chest.* 2001 Apr; 119(4):1114-1122.

Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, **Danziger LH**. Long-term Clarithromycin Decreases Prednisone Requirements in Elderly Patients with Prednisone-Dependent Asthma. *Chest.* 2000;118:1826-1827.

Delgado G, Neuhauser M, Bearden D, **Danziger L**. Quinupristin-Dalfopristin: An Overview. *Pharmacother.* 2000;20:1469-1485.

Donald P, Sirgel F, Kanyok T, **Danziger L**. Early Bactericidal Activity of Paromomycin (Aminosidine) in Patients with Smear Positive Pulmonary Tuberculosis. *Antimicrob Agents Chemother.* 2000;44:3285-3287.

Ventor F, et al. Jung R, Messick C, Pendland S, Tesoro E, Losoendahl K, Schriever C, **Danziger L**. Postantibiotic Effects and Bactericidal Activities of Clarithromycin-14 Hydroxy-Clarithromycin Versus Amoxicillin-clavulanate, Against Anaerobes. *Antimicrob Agents Chemother.* 2000;44:778-779.

Pendland S, Prause J, Neuhauser M, Boyea N, Hackleman J, **Danziger L**. In Vitro Activity of a New Ketolide, ABT-773, Alone and in Combination with Amoxicillin, Metronidazole and Tetracycline Against *Helicobacter pylori*. *Antimicrob Agents Chemother.* 2000 Sep;44(9):2518-2520.

Danziger L. Beyond Bacterial Killing: Immunopharmacologic Effects of Macrolides. *Infections in Medicine.* 1999;16(Suppl E):17-21.

Pendland S, Diaz-Linares M, Garey K, Woodward J, Ryu S, **Danziger L**. Bactericidal Activity and Postantibiotic Effect of Levofloxacin Against Anaerobes. *Antimicrob Agents Chemother*. 1999; 43:2547-2549.

Meyer J, Ryu S, Pendland S, Kanyok T, **Danziger L**. In-vitro Synergy Study of Paromomycin with Metronidazole Alone or Metronidazole plus Hydroxymetronidazole Against *H. pylori*. *J Antimicrob Chemother*. 1999;43:403-406.

Meropol NJ, Wood DE, Nemunaitis J, (Leukine Surgical Prophylaxis Study Group; **Danziger, L**. et al). Randomized, Placebo-controlled, Multicenter Trial of Granulocyte-macrophage Colony-stimulating Factor as Infection Prophylaxis in Oncologic Surgery. *J Clin Oncol*. 1998 Mar; 16(3):1167-1173

Messick C, Mamdani M, McNicholl I, **Danziger L** et al. Pharmacoeconomic Analysis of Ampicillin/Sulbactam versus Cefoxitin in the Treatment of Intraabdominal Infections. *Pharmacother*. 1998;18:175-183.

Messick C, Pursell K, Rodvold K, Wiley T, **Danziger L**. Penetration of Amphotericin B into the Biliary Tract of an Orthoptic Liver Transplant Patient with Candidal Cholangitis. *J of Infect Dis Pharmacother*. 1998;2:39-45.

Rodvold K, **Danziger L**, Quinn J. Single Daily Doses of Aminoglycosides. *Lancet* (editorial). 1997;350:1412.

Martin S, Pendland S, Chen C, Schreckenberger P, **Danziger L**. In Vitro Activities of Clarithromycin and Its Hydroxymetabolite Against *Legionella* spp. *Diagnostic Microbiology and Infectious Diseases*. 1997;29:167-171.

Occhipinti D, Pendland S, Schoonover L, Rypins E, **Danziger L** Rodvold K, Pharmacokinetics and Pharmacodynamics of Two Multiple-Dose Piperacillin-Tazobactam Regimens. *Antimicrob Agents Chemother*. 1997;41:2511-2517.

Pendland S, Martin S, Chen C, Schreckenberger P, **Danziger L**. Comparison of Charcoal and Starch-Based Media for Testing Susceptibilities of *Legionella* Species to Macrolides, Azolides and Fluoroquinolones. *J Clin Microbiol*. 1997;35:3004-3006.

Gotfried M, Killian A, Servi R, **Danziger L**, Rodvold K. Oral Clarithromycin Versus Parenteral Erythromycin for the Treatment of Community Acquired Pneumoniae in Hospitalized Patients. *Clin Drug Invest*. 1997;14:23-34.

Rodvold K, Gotfried M, **Danziger L**, Servi R. Intrapulmonary Steady-State Concentrations of Clarithromycin and Azithromycin in Healthy Adult Volunteers. *Antimicrob Agents Chemother*. 1997; 41:1399-1402.

Kanyok T, Killian A, Rodvold K, **Danziger L**. Pharmacokinetics of intramuscular Aminosidine in healthy subjects. *Antimicrob Agents Chemother*. 1997;41:982-986.

Meyer J, Ryu S, Pendland S, **Danziger L**. In Vitro Synergy Testing of Clarithromycin and 14-Hydroxy Clarithromycin with Amoxicillin or Bismuth Against *Helicobacter*. *Antimicrob Agent Chemother*. 1997; 41:951-956.

Messick C, **Danziger L**. Therapeutic Modalities for Mechanical Cleansing of the Colon. J Am Pharm Assoc. 1996(July); NS36:439-442.

Martin S, Pendland S, Chen C, Schreckenberger P, **Danziger L**. In vitro Synergy Testing of Macrolide-Quinolone Combination Against 41 Clinical Isolates of *Legionella*. Antimicrob Agents Chemother. 1996; 40:1419-1421.

Cooksey J, **Danziger L**, Ervin N, et al. Problem-Based Learning in an Interdisciplinary Community-Based Primary Care Course. Teaching and Learning in Medicine. 1995;7:241-245.

Fish D, Piscitelli S, **Danziger L**. Development of Resistance During Antimicrobial Therapy: a Review of Antibiotic Classes and Patient Characteristics. Pharmacotherapy. 1995;15:279-291.

Occhipinti D, Schoonover L, Rodvold, **Danziger L**. Evaluation of a new beta lactamase inhibitor combination antibiotic: Piperacillin/tazobactam. Ann Pharmacother. 1995;29:501-514.

Danziger L, Pendland S. Review of Bacterial Resistance. Am J Health System Pharm. 1995;52:(Suppl)53-58.

Occhipinti D, Gubbins P, Schreckenberger P, **Danziger L**. Frequency, Pathogenicity and Microbiologic Outcome of Non-Candida albicans Candiduria. Eur J Clin Micro. 1994;13:459-467.

Martin S, **Danziger L**. Use of Continuous Infusion Diuretics in Critically Ill Patients. Critical Care Medicine. 1994;22:1323-1329.

Gubbins P, Occhipinti D, **Danziger L**. Surveillance of Treated and Untreated Funguria in a University Hospital. Pharmacotherapy. 1994;14(4):463-470.

Pendland S, Piscitelli S, Schreckenberger P, **Danziger L**. In vitro Activity of Metronidazole and its Hydroxy Metabolite Against *Bacteroides spp*. Antimicrob Agents Chemother. 1994;38:2106-2110.

Danziger L, Piscitelli S, Occhipinti D, et al. Steady State Pharmacokinetics of Cefoperazone and Sulbactam in Patients with Acute Appendicitis. Ann Pharmacother. 1994;28:703-707.

Danziger L, Martin S, Blum R. Neurotoxicity of Meperidine in Cirrhotic Patients. Pharmacotherapy. 1994;14:235-238.

Danziger L, Schoonover L, Kale P, Resnick D. *Eikenella corrodens* as an Intraabdominal Pathogen. The American Surgeon. 1994;60:296-299.

Fish D, Gotfried M, **Danziger L**, Rodvold K. Penetration of Clarithromycin into Lung Tissue from Patients Undergoing Lung Resection. Antimicrob Agents Chemother. 1994;38:876-878.

Piscitelli S, Hoffman H, **Danziger L**. Oral Antibiotic Usage in Hospitalized Patients. Hospital Formulary. 1994;29:100-105.

Kanyok T, Jagannath C, Reddy V, **Danziger L**, Gangadharam P. The Invitro activity of Aminosidine (Paromomycin) against a Multidrug Resistant *Mycobacterium tuberculosis* Infection in C57BL/6 Mice. Antimicrob Agents Chemother. 1994;38:170-173.

- Kanyok T, Reddy M, Jagannanth C, **Danziger L**, Gangadaharam P. Invitro Susceptibilities of *M. tuberculosis* and *M. avium complex* to Paromomycin. *J Antimicrob Chemother.* 1994;33:323-327.
- Kanyok T, Novak R, **Danziger L**. Treatment of Cryptosporidial Diarrhea: A Review. *Ann Pharmacother.* 1993;27:1460-1462.
- Piscitelli S, Occhipinti D, **Danziger L**, Hill C, West D, Fischer J. The Role of the Pharmacist in a Dapsone Compliance Clinic. *Ann Pharmacother.* 1993;27:1526-1532.
- Danziger L**, Kanyok T, Novak R, Treatment of Cryptosporidial Diarrhea in an AIDS Patient with Paromomycin. *Ann Pharmacother.* 1993;27:1460-1463.
- Danziger L**, Fish D, Wesley L. Aztreonam Hypersensitivity in a Beta-Lactam Allergic Patient. *Infectious Diseases in Clinical Practice.* 1993;2:389-393.
- Fish D, **Danziger L**. Bacterial Infections in AIDs Patients: The Unforgotten Pathogens. *Pharmacotherapy, (Part II).* 1993;13(6):543-563.
- Fish D, **Danziger L**. Bacterial Infections in AIDs Patients: The Unforgotten Pathogens. *Pharmacotherapy, (Part I).* 1993;13(5):415-439.
- Gubbins P, Piscitelli S, **Danziger L**. Candidal Urinary Tract Infections: A Comprehensive Review of Their Diagnosis and Management. *Pharmacotherapy.* 1993;13(2):110-127.
- Piscitelli S, **Danziger L**, Hill C, West D, Fischer J. Effectiveness of a Dapsone Compliance Program in Leprosy. *Inter J Derm.* 1993;32:206-209.
- Occhipinti D, Itokazu G, **Danziger L**. Selective Gastrointestinal Tract Decontamination in the ICU patient: A Review. *Pharmacotherapy.* 1992;12(6 Pt 2):50S-63S.
- Lau A, Lam N, Piscitelli S, Wilkes L, **Danziger L**. Clinical Pharmacokinetics of Metronidazole and Nitro-imidazole Antibiotics. *Clin Pharmacokinetic.* 1992;25(5):238-364.
- Piscitelli S, Fish D, **Danziger L**, Gotfried M, Rodvold K. Diagnosis of Nosocomial Pneumonia. *Infections in Medicine.* 1992 Nov:27-46.
- Fish D, Piscitelli S, **Danziger L**, Gotfried M, Rodvold K. Treatment of Nosocomial Pneumonia. *Infections in Medicine.* 1992 Oct;17-32.
- Fish D, Hoffman H, **Danziger L**. Survey of Antibiotic-Impregnated Bone Cement and Cement Bead Use in United States Hospitals. *Am J Hosp Pharm.* 1992;49:2469-2474.
- Piscitelli S, Schreckenberger P, Shwed J, **Danziger L**. *Streptococcus milleri*: A Forgotten Pathogen. *Eur J Clin Microbiol Infect Dis.* 1992;11:491-498.
- Wilkes L, **Danziger L**, Rodvold K. Pharmacokinetics of Phenobarbital in Obesity: A Case Report. *Clin Pharmacokinetics.* 1992;22(6):481-484.
- Piscitelli S, Rodvold K, **Danziger L**. A Review of Clarithromycin and Azithromycin. *Clinical Pharmacy.* 1992;11:137-152.

Itokazu G, **Danziger L**. Ampicillin-Sulbactam and Ticarcillin-Clavulanic Acid: A Comparison of Their In Vitro Activity and Review of Their Clinical Efficacy. *Pharmacotherapy*. 1991;11(5):382-414.

Wilkes L, Fish D, **Danziger L**. Pharmacotherapy of Soft Tissue Infections. *J Pharm Pract*. 1991;4:192-203.

Shwed J, **Danziger L**, Wojtynek J, et al. A Comparative Evaluation of the Safety and Efficacy of Cefotetan and Cefoxitin in Surgical Prophylaxis. *DICP: Ann Pharmacotherapy*. 1991;25:10-13.

Brown R, Kruse J, Counts G, Russell A, Christou N, Sands M, and Endotracheal Study Group (Altman F, Bivins R, **Danziger L**, Ericsson C, et al). Double-blind Study of Endotracheal Tobramycin in the Treatment of Gram-Negative Pneumonia. *Antimicrob Agents Chemother*. 1990; 34:269-272.

Stellato, T, **Danziger L**, Hau T. A-Randomized Double-Blind Trial of Oral, Systemic, or the Combination of Oral and Systemic Antibiotics for Prophylaxis in Colorectal Surgery. *American Surgeon*. 1990;56:251-254.

Danziger L, Furmaga K, Rodvold K, Bombeck CT, Fischer J. Nizatidine Suppression of Basal Gastric Acid Output: A comparison of Two IV Dosage Regimens. *J Clin Pharmacol*. 1989; 29:946-952.

Itokazu G, **Danziger L**. Therapeutic Drug Monitoring in Patients with Ulcers. *J Pharm Pract*. 1989;2:382-392.

Majerus T, Dasta J, Bauman J, **Danziger L**, Ruffolo R. Dobutamine: Ten Years Later *Pharmacotherapy*. 1989;9(4):245-259.

Danziger L, Creger R, Shwed J, Stellato T, Hau T. A Randomized Trial of Gentamicin and Clindamycin versus Imipenem in Serious Infections. *Pharmacotherapy*. 1988; 8:315-318.

Shwed J, **Danziger L**. Intraventricular Aminoglycosides in Bacterial meningitis. *Drug Therapy*. 1988;13:73-79.

Stellato T, **Danziger L**. Fetal Salvage with Maternal Total Parenteral Nutrition: The Pregnant Mother as Her Own Control. *JPEN*. 1988;12:412-414.

Hassan E, **Danziger L**. Metabolic Response to Injury. *Traum Q*. 1988;4:1-7.

Stellato T, Townsend M, Gordon N, **Danziger L**, et al. Effects of muramyl dipeptide and core body temperature on peritoneal bacterial clearance. *Arch of Surg*. 1988;123:465-469.

Stellato T, **Danziger L**, Gauderur M, Ferron J, Hau T. Moxalactam vs. Tobramycin-Clindamycin. A Randomized Trial in Secondary Peritonitis. *Arch Surg*. 1988;123:714-717.

Danziger L, Hassan E. Antimicrobial Prophylaxis of Gastrointestinal Surgical Procedures and Treatment of Intraabdominal infections. *Drug Intell Clin Pharm*. 1987;2:406-416.

Danziger, L. Controversies in Antimicrobial Therapy: Innovative Methods of Administration. *Am J Hosp Pharm*. 1986;43:646-652.

- Creger R, Cowan R, Nearman H, **Danziger L**. Cerebrospinal Fluid Penetration of Moxalactam in Ventriculostomy Patients. *J Inf Dis*. 1985;28:839-841.
- Stellato T, **Danziger L**, Nearman H, Creger R. Inadvertent Intravenous Administration of Enteral Diet. *JPEN*. 1984;8:453-456.
- Hanus P, **Danziger L**. Treatment of Chronic Bacterial Prostatitis. *Clin Pharm*. 1984(1);3:49-55.
- Danziger L**, Horn J. Disopyramide-Induced Urinary Retention: Report of Nine Cases and Review of the Literature. *Arch Intern Med*. 1983;143(9):1683-1686.
- Danziger L**, Cowan R. Interdisciplinary grand rounds. Legal consequences of prescribing an approved drug for a non-approved use: cimetidine: a case in point. *Health Matrix*. 1983 Winter; 1(1):41-43.
- Hau T, Nishikawa R, **Danziger LH**. Antibiotics in Surgery, *Surg Annu*. 1983;15:177-205.
- Stomberg B, Davis R, **Danziger L**. Relationship of Serum Transferrin to Total Iron Binding Capacity in Nutritional Assessment, *JPEN* 1982; 6(5):392-394.
- Horn J, **Danziger L**, Davis R, Warfarin Induced Skin Necrosis: Report of Four Cases and a Review of the Literature. *Am J Hosp Pharm*. 1981;38(11):1763-1767.
- Gorber A, Kearns G, Yokel R, **Danziger L**. . Repeated Naloxone Administration for Morphine Overdose in a One-Month Old Infant. *Pediatrics* 1979;63(4):606-606.

Newsletters/Proceedings/Monographs/Guidelines

- Slover C, Danziger LH**. Lactobacillus: A Review. *Clinical Microbiology Review Letter*. Vol 30, No. 4. Pages: 23-24. February 15, 2008.
- Danziger L**, Rupali J. Evaluation of the Clinical Use of the Newer Macrolides and Ketolides. *Power-Pak CE* 2005.
- Danziger L**. Antibiotic Rotation in the ICU B Con, *Pharmacy Practice News*, Special Report, December 2002.
- Danziger L**, Koontz F, Schito G et al. Antibiotic resistance and therapeutic success: A clinical contradiction. *Special Supplement; Infections in Medicine*, March 1999.
- Danziger L**, et al. Surgical Antimicrobial Prophylaxis. *Am J Health-Syst Pharm*.1999;56:1839-88.
- Danziger L**, et al. NonSurgical Antimicrobial Prophylaxis. *Am J Health-Syst Pharm*. 1999;56:1201-50.
- Danziger L**, Jones R. Antimicrobial Chemotherapy for Surgery Associated Infections. *Infectious Disease Special Edition*. Vol. 1; October 1998.
- Danziger L**, Meyer J. Overview of Treatment and Pathophysiology of Peptic Ulcer Disease. *CE*

PRN, Sept. 1997.

Lesch C, **Danziger L**. Once Daily Aminoglycoside Dosing. *Keeposted*(Illinois Council of Health-System Pharmacists, 1997;33-March(3):11-16.

McNicoll I, **Danziger L**, Rodvold K. The Diagnosis and Treatment of Community Acquired Pneumonia. *Diversified Bulletin*,1996.

Danziger L, Jones R. Empiric and Directed Antimicrobial Chemotherapy for Surgical Infections. *Pharmacy Practice News*, June 1996.

Meyer J, **Danziger L**. No Bacteria, No Ulcer? *Health Wellness Letter*, March 1995.

Danziger L, Pendland S, Jones R. Empiric and Directed Antimicrobial Chemotherapy for Surgical Infections. *Pharmacy Practice News*. August 1994.

Danziger L. The Extended Spectrum Beta-Lactamases and Their Clinical Significance. University of Kentucky Press. January 1994.

Martin S, **Danziger L**. Use of Continuous Infusion Diuretics in Critically Ill Patients. *Clinical Trends in Hospital Pharmacy*. March 1994.

Gubbins P, Piscitelli S, **Danziger L**. Urinary Tract Infections caused by Candida Species. *Pharmacy Times*. 1993 January; pgs:120-129.

Danziger L, et al. Task Force on Antimicrobial Prophylaxis in Surgery: Guidelines. *Am J Health-Syst Pharm*.1992; 11:483-513.

Fish D, **Danziger L**. The FDA Drug Approval Process. *The Wellness Newsletter* 1993;1:1-2.

Wilkes L, **Danziger L**. Hepatitis C: A Review of Current Treatments. *Clinical Trends in Hospital Pharmacy* Vol.5 No.3, 1991.

Itokazu G, **Danziger L**. Treatment of Gastric Ulcer Disease. *CE PRN* Vol. 12 No. 7, 1990.

Danziger L. Use of heparin with IV fat emulsions, *Ask the Experts Column*, *Aspen Update* 5:7, 1983.

Letters

Occhipinti D, Schoonover L, **Danziger L**. Bladder Irrigation with Amphotericin B for the Treatment of Patients with Candiduria. *Clin Inf Dis*. 1993;17:812-813.

Danziger L. Prophylaxis with Aztreonam plus metronidazole during appendectomy. *Clin Pharm*. 1993;12:803.

Danziger L. Prophylaxis with Aztreonam plus Metronidazole During Appendectomy. *Am J Hsop Pharm*. 1993;50:2314-2315.

Gubbins P, Piscitelli S, **Danziger L**. Urinary Tract Infections caused by Candida Species. *The*

Journal of Practical Nursing. 1993, June;pg:23-34.

Fish D, Piscitelli S, **Danziger L**. Resistance With The Fluoroquinolones: Is It Really a Problem. Archives Internal Medicine. 1992;152:1329-1330.

Stellato T, Gordon N, **Danziger L**. Antibiotics in Colorectal Surgery. Ann Surg. 1991;213:375-376.

Dasta J, Bauman J, **Danziger L**, et al. Dobutamine vs Dopamine: Another Look. Pharmacotherapy. 1990;10:417-418.

Glazier H, **Danziger L**, Green J. Clinical Pharmacists and the Undereducated Physician. 1983 Nov 17;309(20):1257-8.

Book Chapters

Itokazu G, Bearden D, **Danziger L**. In Applied Therapeutics: The Clinical Use of Drugs 10th Edition. Infectious Diarrhea., Koda-Kimble M, Young L, Kradjan W, Guglielmo B, Alldredge B, Corelli R. eds. Lippincott Williams & Wilkins, New York, 2013. Chapter 66. pgs 1559-1580.

Fish D, Pendland S, **Danziger L**. In Pharmacotherapy: A Pathophysiologic Approach Soft tissue Infections. Eds., DiPiro J. et al. Pub. McGraw Hill (Medical), 8th Edition. 2011. Chapter 119. pgs 1893-1912.

Neuhauser M, **Danziger L**. Beta Lactam Antibiotics, Drug Interactions in Infectious Diseases; Eds Piscitelli S, Rodvold K, Pai M. 3rd Edition 2011. Chapter 7. pgs 203-242.

Fish D, Pendland S, **Danziger L**. In Pharmacotherapy: A Pathophysiologic Approach Soft tissue Infections. Eds., DiPiro J. Pub. McGraw Hill (Medical), 7th Edition. 2008. Chapter 114. pgs 1801-1819.

Jung R, Gotfried M, **Danziger L**. In Antibiotics as Anti-Inflammatory and Immunomodulatory Agents. Bruce Rubin and Jun Tamaoki, eds., Birkhauser Verlag, Boston, Basel, Berlin. 2005. Benefits of Macrolides in the Treatment of Asthma. pgs 205-219.

Itokazu G, Bearden D, **Danziger L**. In Applied Therapeutics: The Clinical Use of Drugs 8th ed. Infectious Diarrhea., Koda-Kimble M, Young L, Kradjan W, Guglielmo B, Alldredge B, Corelli R. eds. Lippincott Williams & Wilkins, New York, 2005. Gastrointestinal Tract Infections. Chapter 62. pgs 62-1 thru 62-23.

Pendland S, Fish D., **Danziger L**. In Pharmacotherapy: A Pathophysiologic Approach Soft tissue Infections. Eds., DiPiro J. Pub. McGraw Hill (Medical), 6th Edition. 2005. Chapter 108. pgs 1977-1997.

Danziger L, Fish D. In Pathophysiologic Approach to Clinical Pharmacy. Soft tissue Infections. Eds., DiPiro J. Pub. Elsevier, 5th Edition. 2002. Chapter 108. pgs 1185-1188.

Danziger L, Itokazu G, Bearden D. In Applied Therapeutics 7th Ed. Gastrointestinal Infections. Young L, Koda-Kimble M, eds. Applied Therapeutics, Inc. 2001. Chapter 60.

Neuhauser M, **Danziger L**. Beta Lactam Antibiotics, Drug Interactions in Infectious Diseases; Eds Piscitelli S, Rodvold K, 2001. Chapter 7. pgs 151-184.

Danziger L, Fish D. Pathophysiologic Approach to Clinical Pharmacy. Soft tissue Infections. Eds., DiPiro J. Pub. Elsevier, 4th Edition. 1999. Chapter 100. pgs 1700-1717.

Fiscella R, Diaz-Linares M, **Danziger L**. Pharmacology of Drugs Used in the Treatment of AIDS and Related Infections. In: Clinical Optometric Pharmacology and Therapeutics. 2nd Edition, Ed: Onfrey B., Lippincott, New York. 1996.

Danziger L, Itokazu G . In Applied Therapeutics 6th Ed. Gastrointestinal Infections. Young L, Koda-Kimble M, eds. Applied Therapeutics, Inc.. 1996. Chapter 60.

Occhipinti D, Schoonover L, **Danziger L**. Use of beta-lactamase inhibitor combination products in intra-abdominal infections, 1st ed. Pharmacology of piperacillin/tazobactam in intraabdominal infections. August 1995.

Danziger L, Fish D. Pathophysiologic Approach to Clinical Pharmacy. Soft tissue Infections. Eds., DiPiro J. Pub. Elsevier, 3rd Edition. 1995.

Schoonover L, Occhipinti D, **Danziger L**. Use of beta-lactamase inhibitor combination products in obstetric and gynecologic infections, 1st ed. Pharmacology of piperacillin/tazobactam in obstetric and gynecologic infections. August 1995.

Danziger L, Itokazu G, In Applied Therapeutics 6th Ed. Gastrointestinal Infections. Young L, Koda-Kimble M, eds. Applied Therapeutics, Inc. 1994. Chapter 40.

Danziger L, Hassan E, Pathophysiologic approach to Clinical Pharmacy. Soft tissue Infections. Second Edition; Eds., DiPiro J. Pub. Elsevier. 1992. pgs. 1122-1138.

Gross M, Itokazu G, **Danziger L**. In Applied Therapeutics 5th Ed. Gastrointestinal Infections. Young L, Koda-Kimble M, eds. Applied Therapeutics, Inc. 1992. Chapter 40.

Fiscella R, Piscitelli S, **Danziger L**. Pharmacology of Drugs Used in the Treatment of AIDS and Related Infections. In: Clinical Optometric Pharmacology and Therapeutics. Ed: Onfrey B., Lippincott, New York. 1993.

Danziger L, Schwed J. Topics of Pharmacy: Routes of Administration Innovative: Methods of Antibiotic Administration. Ed., Florence A, Salole D. Pub. Butterworth & Co. 1990.pgs. 137-155.

Danziger L, Rodvold K., Stellato T. Fluoroquinolones in The Treatment Of Infectious Diseases. Use of Fluoroquinolones in the Treatment and Prophylaxis of Surgical Infections. Pub. Physicians & Scientists Publishing Co. 1990. pgs. 177-193.

Danziger L, Hassan E. Pathophysiologic Approach to Clinical Pharmacy. Soft tissue Infections. Eds., DiPiro J. Pub. Elsevier. 1988. pgs. 1122-1138.

Hau T, Nishikawa R, **Danziger L**. Surgery Annual vol 15 Antibiotics in Surgery, Ed. L. Nyhus, Pub. Appleton-Century-Crofts. 1983. pgs. 117.

Abstracts at Scientific Meetings

Z. Kassamali, Wieczorkiewicz S, **Danziger L**. Behind Closed Doors: Medication Storage and Disposal in the Home. 50th Annual Meeting of the Infectious Diseases Society of America. San Diego, California, October 2012. Abstract 1609.

Z. Kassamali, **Danziger L**, Glowacki RC, Schwartz DC. How Low Can You Go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections at a U.S. public hospital. 22th European Congress on Chemotherapy Microbiology and Infectious Diseases (ECCMID). London, England. March 2012. Poster P-849.

Regen S, Easterling J, **Danziger L**, Hunkler R, Suda K, A Three-Year Analysis of Antiviral Prescribing Trends in the United States. 49th Annual Meeting of the Infectious Diseases Society of America. Boston, USA, October 2010. Abstract 1139.

Suda K, **Danziger L**, Garey K. Antimicrobial Prescription Data Reveal Wide Geographic Variability in Antimicrobial Use in the United States, 2009. 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, Canada, October 2010. Abstract 339.

Jourjy J, Wieczorkiewicz S, **Danziger L**. Evaluation of Hospitalized Patients with Clostridium difficile Infection at An Urban Teaching Institution. 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, Canada, October 2010. Abstract 448.

McMahon D., Langridge S, **Danziger LH**. Evaluation of Empiric and Definitive Treatment of Clostridium difficile-Associated Diarrhea. 46th Annual Meeting of the Infectious Diseases Society of America and 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC. October 2008. Abstract K-3512.

Laohavaleeson S, Jain R, **Danziger LH**. The Characterization of Intravenous Colistin use at an U.S. Urban Teaching Institution. 46th Annual Meeting of the Infectious Diseases Society of America and 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC. October 2008. Abstract K-519.

Joseph J, **Danziger LH**, Schreckenberger P, Quinn JP, Garey K. Chicagoland Antimicrobial Susceptibility Trends in Teaching (TH) versus Community Hospitals (CH) between 1994-2005. 45th Annual Meeting of the Infectious Diseases Society of America, Toronto, San Diego. October 2007.

Patterson TF, Kirkpatrick WR, Alexander B, **Danziger L**, et al. Efficacy and Safety of Caspofungin (CAS) in a Real World Clinical Setting. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL. October 2007.

Slover CM, Sheth V, **Danziger LH**, Tu E, Fiscella RG. Evaluation of Topical Linezolid (LN), Daptomycin (DP), and Tigecycline (TG) Compared to Vancomycin (VN) in a Rabbit (RB) Model of *Streptococcus pneumoniae* (SP) Corneal Ulceration (CU). Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL. 2007.

Danziger LH, Notario G, Smith A, Dezelan C, A Comparison of Recurrence Rates and Antibiotic (ABX) Choice in Patients (Pts) Diagnosed with Acute Bacterial Exacerbations of Bronchitis (ABECB).

44th Annual Meeting of the Infectious Diseases Society of America. Toronto, ON, Canada. October 2006.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Physician Specialty and Antimicrobial Prescribing Trends for Respiratory Tract Infections in the United States. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA. September 2006.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Antimicrobial Prescribing Practices by Physician Specialty in the United States. 16th European Congress on Chemotherapy Microbiology and Infectious Diseases (ECCMID). Nice, France. March 2006.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Outpatient Upper and Lower Respiratory Tract Infection Antimicrobial Prescribing Patterns: A Three Year Analysis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. December 2005.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Three Year Nation-Wide Prescribing Patterns for Macrolides. US. 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, October 2005.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Three-Year Analysis of Antibiotic (AB) Prescribing Patterns (PP) to Patient (PT) Diagnoses (DX). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. October 2004.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. A 3 year Nationwide Analysis of Outpatient Antimicrobial Prescribing (Encore Presentation). American College of Clinical Pharmacy. Dallas, TX. October 2004.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. "A 3 year Nationwide Analysis of Outpatient Antimicrobial Prescribing." 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA. October 2004. Abstract 446.

Jain R, Schriever C, **Danziger L** et al. Failure to Detect the IS6110 repetitive DNA Element of *Mycobacterium tuberculosis* in Exhaled Breath Condensate of Patients with Active Pulmonary Tuberculosis, 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic. May 2004. Abstract P-1484.

Danziger LH. The Safety of 750 mg Levofloxacin. Int J Infect Dis., 2004;8(Suppl):S177, Cancun, Mexico. March 2004. Poster 57.002.

Jain R, Gunderson S, Ristow KL, Schreckenberger P, **Danziger LH**. Prevalence of Acinetobacter Infections over a 9-Year Period in an Inner City Hospital. Infectious Diseases Society of America 41st Annual Meeting. San Diego, CA. October 2003.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Analysis of Differences in Prescribing Patterns between Patients with Upper and Lower Respiratory Tract Infections. Infectious Diseases Society of America 41st Annual Meeting. San Diego, CA. October 2003.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Antibiotic Failures in an Outpatient, National, Managed Care Database. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. September 2003.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. Relationship of Antibiotic Prescribing Patterns to Patient Diagnoses." Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. September 2003.

Suda KJ, Garey KW, Bertram CT, **Danziger LH**. A Nationwide Analysis of Outpatient Antimicrobial Prescribing. Infectious Diseases Society of America 40TH Annual Meeting. Chicago, IL. October 2002.

Gunderson S, Ristow K, Schreckenberger P, **Danziger LH**. 8-Year Trends in BSIs Among Hospitalized Patients in an Inner City Institution, and Increase in Enterococcal Bacteremia. 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA. 2002. Abstract K-90.

Gunderson S, Kelar S, Hayes R, Quinn JP, **Danziger LH**. Minimum Inhibitory Concentrations and Time-Kill Analysis of ABT-492, A New Quinolone, Against Penicillin Sensitive and Penicillin Resistant *Streptococcus pneumoniae*. 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego CA. 2002. Abstract F-547.

Drusano G, Preston S, Gotfried M, **Danziger L**, Rodvold K. The Penetration of 750mg of Levofloxacin Administered Intravenously into the Epithelial Lining Fluid (ELF). 10th International Congress on Infectious Diseases. Singapore. 2002.

Rodvold K, **Danziger L**. Intrapulmonary Concentrations of Clarithromycin and Azithromycin: Impact of Differences in Methodology on Variability of Results. ICMASKO 6. Bologna, Italy. January 2002.

Jain R, Duda K, Garey K, **Danziger LH**. A Two Year Analysis of Susceptibilities of *Acinetobacter* spp. In Patients with Documented Bacteremia. 36th ASHP Midyear Clinical Meeting. New Orleans, LA. December 2001.

Suda K, Garey K, Manduru-Roa M, Goetz A, Gupta V, **Danziger L**. Nationwide Surveillance of Antimicrobial Resistance Patterns in Non-teaching Community Hospitals the year 2001. ACCP 2001 Annual Meeting Tampa, FL. *Pharmacotherapy* 2001;21:1275, Abstract 126.

Manduru-Roa M, Suda K, Garey K, Geotz A, Gupta V, **Danziger L**. Relationship Between Infectious Disease Practices and Gram Positive Resistance in Community Hospitals Throughout the United States. ACCP 2001 Annual Meeting. Tampa, FL. *Pharmacotherapy* 2001;21:1275, Abstract 125.

Cannon J, Patarachayakul S, Fiscella R, Delaba F, Piscitelli S, Delgado G, Garey K, **Danziger L**. The Comparative Toxicity and Concentrations of Intravitreally Administered Amphotericin B Deoxcholate, Amphotericin B Lipid Complex and Liposomal Amphotericin B in a Rabbit Model. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada. September 2000. Abstract 2122.

Garey K, Tesoro E, Muggia V, Pasquier O, Ausman J, **Danziger L**, Rodvold K. Cerebrospinal Fluid Concentrations of Quinupristin-Dalfopristin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada. September 2000. Abstract 505.

Drusano G, Preston S, Gotfried M, **Danziger L**, Rodvold K. Levofloxacin Penetration into Epithelial Lining Fluid as Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation.

40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada. September 2000. Abstract 660.

Pai M, Prause J, **Danziger L**, Pendland S. The Epidemiology and Susceptibility of Candida Isolates for Mycological Outcomes Assessment. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada. September 2000. Abstract 224.

Neuhauser M, Prause J, Hackleman H, **Danziger L**, Pendland S. *In Vitro* Bactericidal Activity of ABT 773, A New Ketolide, versus Cefuroxime and Amoxicillin/Clavulanate Against High Level Erythromycin Resistant (ermB) *Streptococcus pneumoniae*. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada. September 2000. Abstract 2162.

Garey KW, Liang P, Itokazu G, Schwartz D, Rydman R, **Danziger LH**, Rodvold KA and the Chicago Area Resistance Project (CARP). A North American (NA) Survey of Infectious Disease Pharmacists (IDP) Perspectives on Antibiotic Control Programs (ACP). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada. September 2000. Abstract 86.

Neuhauser M, Itokazu G, **Danziger L**, Karam G, Rydman R, Weinstein R, Quinn J. Increasing Resistance to Fluoroquinolones and Ceftazidime Among Gram Negative Bacilli from ICUs Patients. 38th Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA. September 2000. Abstract 184.

Patharachayakul S, Schreckenberger P, **Danziger L**. Risk Factors and Treatment Outcomes of Urinary Tract Infections due to Enterococcus. 38th Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA. September 2000. Abstract 484.

Sheehan J, Garey K, Cannon J, Pai A, **Danziger L**. Amphotericin B Deoxycholate (AB) versus Lipid Associated Amphotericin B Products for the Treatment of Documented Aspergillus/Zygomycetes Pulmonary Infections. 38th Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA. September 2000. Abstract 306.

Garey KW, Neuhauser MM, Jung R, Schreckenberger PC, **Danziger LH**, Rubinstein I. Pathogen Frequency (PF) and Antimicrobial Susceptibility (AS) Patterns Differ within Inpatient Wards (IW) Of a Large Inner-City Hospital. 38th Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA. September 2000. Abstract 91.

Garey KW, Neuhauser MM, Jung R, Schreckenberger PC, Rubinstein I, **Danziger LH**. Outpatient Pathogen Frequency and Antimicrobial Susceptibilities in an Inner-City Chicago Hospital. 100th General Meeting of the American Society for Microbiology. Los Angeles, CA. May 2000.

Neuhauser MM, Garey KW, Jung R, Schreckenberger PC, Rubinstein I, **Danziger LH**. Antibigram Susceptibility Patterns Based upon Limiting One Positive Culture per Patient. 100th General Meeting of the American Society for Microbiology. Los Angeles, CA. May 2000.

Garey KW, Neuhauser MM, Radice AL, Robbins RA, **Danziger LH**, Rubinstein I. Protein, Nitrate/Nitrite, and Cytokine Concentrations in Exhaled Breath Condensate of Young Smokers. 96th Annual International Conference of the American Thoracic Society. Toronto, ON, Canada. May 2000.

Garey KW, Khan I, Varma S, Varma SR, Dhanini H, **Danziger LH**, Rubinstein I. Clinical

Manifestations of Sarcoidosis in Predominantly African-American Patients from Inner City Chicago. 96th Annual International Conference of the American Thoracic Society. Toronto, ON, Canada. May 2000.

Garey KW, Khan IJ, Varma S, Gotfried MH, Rubinstein I, **Danziger LH**. Decreased Prednisone Requirements With Extended Use Of Clarithromycin In Elderly Patients With Corticosteroid-Dependent Asthma. 96th Annual International Conference of the American Thoracic Society. Toronto, ON, Canada. May 2000.

Garey KW, Neuhauser MM, Jung R, **Danziger LH**, Rubinstein I. Repeated Positive Cultures in Patients Heralds Increased Antimicrobial Resistance. 9th International Congress on Infectious Diseases. Buenos Aires, Argentina. April 2000.

Shin G, Desai S, Jung M, Moody L, **Danziger L**. Appropriateness of Levofloxacin Usage in a Tertiary Academic Institution. Midyear Clinical Meeting, ASHP, Orlando, FL. December 1999.

Cannon J, Garey KW, Jung R, Delgado Jr G, Sofronici R, Martin S, **Danziger L**. Concurrent and retrospective analysis of Abelcet (AB) and AmBisome (AM). 37th Annual Meeting of the Infectious Disease Society of America (IDSA). Philadelphia, PA. November 1999.

Cannon J, Garey K, Jung R, Delgado G, Sofronici-Smith R, **Danziger L**. Concurrent and Retrospective Analysis of Nephrotoxicity and Efficacy of ABELCET and AmBisome with Focus on Febrile Neutropenic Patients in an Urban Teaching Hospital. 37th Meeting of the Infectious Disease Society of America. Philadelphia, PA. November 1999. Abstract 268.

Bearden D, Jung R. **Danziger L**. Differential Cytokine Release with Antimicrobials Against *Streptococcus pneumoniae* in Whole Blood. 37th Meeting of the Infectious Disease Society of America. Philadelphia, PA. November 1999. Abstract 167.

Jung R, Bearden DT, **Danziger L**. Effect of ABT-773 and other antimicrobials on the Release of Interleukin 1beta and Interleukin 8 against Haemophilus influenzae in Whole Blood. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999. Abstract 143.

Gotfried MH, Neuhauser MM, Garey KW, Saubolle MA, **Danziger LH**. In vitro Streptococcus pneumoniae (SP) resistance: Correlations with outcomes in patients with respiratory infections. 21st International Congress of Chemotherapy. Birmingham, England. July 1999.

Gotfried M, Neuhauser M, **Danziger L**. Comparison of clinical outcomes of patients with respiratory tract infections with or without resistant *Streptococcus pneumoniae*. 21st International Congress of Chemotherapy, Birmingham, England. July 1999.

Gotfried M, Jung R, Messick C, Rubinstein I, Garey C, Rodvold K, **Danziger L**. Placebo controlled trial evaluating the efficacy of clarithromycin in subjects with corticosteroids. 21st International Congress of Chemotherapy, Birmingham, England. July 1999.

Cannon JM, Delgado Jr., G, Sofronici RO, Jung R, Garey KW, **Danziger LH**. A retrospective and concurrent analysis of Abelcet and Ambisome. 2nd Annual Making a Difference: Trends in Infectious Diseases Pharmacotherapy Conference. Orlando, FL. May 1999.

Garey K, Rodvold K, Killian A, **Danziger L**. Penetration of rifabutin into cerebrospinal fluid of

ventriculostomy patients. American Society for Clinical Pharmacology 100th Annual Meeting. San Antonio, TX. March 1999.

Gotfried M, Rodvold K, **Danziger L**. Intrapulmonary disposition of levofloxacin and ciprofloxacin at steady-state in normal healthy adults. 36th Annual Meeting of the Infectious Disease Society of America. November 1998. Abstract 251.

Jung R, Pendland S, Martin S, **Danziger L**. Bacterial Growth in Perfluorooctyl Bromide. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 1998. Abstract 15976.

Lesch C, Itokazu G, **Danziger L**, Weinstein R. MultiHospital Analysis of Antimicrobial Usage and Resistance Trends. 35th Annual Meeting of the Infectious Disease Society of America. September 1997. Abstract 433.

Chuck S, Onwuta U, Kanyok T. **Danziger L**. In vitro extracellular and intracellular Legionella activity of aminosidine. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, ON, Canada. September 1997.

Flamm R, Gotfried M, Rodvold K, **Danziger L**, Servi R, Palmer R. Antimicrobial Activity of Intrapulmonary Concentrations of Clarithromycin and Azithromycin at Steady State in Normal Healthy Adults. 20th International Congress of Chemotherapy. Sydney, Australia. July 1997.

Diaz-Linares M, Guisto D, **Danziger L**, Cooksey J, Nelson J, Ervin N. Introduction to Community Oriented Health Care for Pharmacy Students Using an Interdisciplinary Approach. AACP Annual Meeting Indianapolis, IN. 1997. Abstract 84.

Pendland S, Diaz M, Woodward J, Seonyoun R, **Danziger L**. Bactericidal Activity of Levofloxacin Against *Bacteroides spp*. Abstract . Abstract E9, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA. September 1996.

Pendland S, Messick C, Woodward J, Seonyoun R, **Danziger L**. In Vitro Synergy Testing of Levofloxacin, Ofloxacin and Ciprofloxacin in Combination with Piperacillin, Ceftazidime, Aztreonam, or Gentamicin Against *Pseudomonas aeruginosa*. Abstract E10. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New Orleans, LA. September 1996.

Killian A, Rodvold K, **Danziger L**, Kanyok T. Pharmacokinetic of Intramuscular Aminosidine in Health Subjects. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New Orleans, LA. September 1996. Abstract A22.

Gotfried M, Rodvold K, **Danziger L**, Servi R. Intrapulmonary Concentrations of Clarithromycin and Azithromycin at Steady-State in Normal Healthy Adults. 3rd Conference on the Macrolides, Azolides and Streptogramins. Lisbon, Portugal. January 1996. Abstract 12.03.

Gotfried M, Killian A, Ervie R, **Danziger L**, Rodvold K. Oral Clarithromycin vs IV Erythromycin for the Treatment of CAP in Hospitalized Patients. 3rd Conference on the Macrolides, Azolides and Streptogramins. Lisbon, Portugal. January 1996. Abstract 12.03.

Meyer J, Ryu S, Pendland S, **Danziger L**. In Vitro Synergy Testing of Clarithromycin and 14-Hydroxy Clarithromycin with Amoxicillin or Bismuth Against *Helicobacter*. 3rd Conference on the Macrolides, Azolides and Streptogramins. Lisbon, Portugal. January 1996. Abstract 5.14.

Ru S, Myer J, **Danziger L**. In-Vitro Susceptibility Testing of *Helicobacter pylori* Against Eight Antimicrobial Agents. Seventeenth Annual Undergraduate Research Seminar. West Virginia University. October 1995.

Pendland S, **Danziger L**. Postantibiotic Effect of Levofloxacin on Bacteroides Species. Infectious Diseases Society of America. San Francisco, CA. September 1995. Abstract 173.

Messick C, Pursell K, Rodvold, **Danziger L**. Penetration of Systemic Amphotericin B into the Biliary Tract of an Adult Orthoptic Liver Transplant Patient with Invasive Fungal Cholangitis. Infectious Diseases Society of America. San Francisco, CA. September 1995. Abstract 357.

Colombo J, Glowacki R, Rodvold K, **Danziger L**. Development of a Pharmaceutical Care Model for HIV Positive Patients. Annual American College of Clinical Pharmacy Meeting. Washington, DC August 1995. Abstract 233.

Giusto D, **Danziger L**, Gratz S, Carter B. The implementation of comprehensive pharmaceutical care services in both a primary care setting and a chain pharmacy setting. Annual American College of Clinical Pharmacy Meeting. Washington, DC. August 1995. Abstract 241.

Cooksey J, **Danziger L**, Ervin N, Groves S, Davis J, Nelson J. Problem-Based Learning in an Interdisciplinary Community Course. Annual Meeting of the Association of American Medical Colleges. 1994.

Occhipinti D, Schoonover L, Bilek M, Schreckenberger P, **Danziger L**. Comparison of Urinary Concentrations of Amphotericin B following Continuous Bladder Irrigation for Susceptibilities. 94th General Meeting of the American Society for Microbiology. Las Vegas, NV. May 1994. Abstract C-492.

Martin S, Pendland S, Chen C, Schreckenberger P, **Danziger L**. In vitro Synergy of Clarithromycin and Its 14-hydroxy Metabolite in Combination with Ciprofloxacin against 21 Clinical Isolates of Legionella. 94th General Meeting of the American Society for Microbiology. Las Vegas, NV. May 1994. Abstract A-34.

Pendland S, Martin S, Chen C, Schreckenberger P, **Danziger L**. Comparison of Charcoal and Starch Based Media to Susceptibility of 33 Clinical Isolates of Legionella to Erythromycin, Clarithromycin, and Ciprofloxacin. 94th General Meeting of the American Society for Microbiology. Las Vegas, NV. May 1994. Abstract C-327.

Martin S, **Danziger L**. Evaluation of Continuous Infusion Furosemide in Critically Ill Patients. 1994 Winter Research Forum of the American College of Clinical Pharmacy. San Diego, CA. February 1994.

Martin S, Pendland S, Chen C, Schreckenberger P, **Danziger L**. In Vitro Synergy Testing of Erythromycin, Ciprofloxacin and Clarithromycin Against 24 Clinical Isolates of Legionella. 2nd Annual Conference on the Macrolides, Azolides and Streptogramins. Venice, Italy. January 1994. Abstract 137.

Pendland S, Martin S, Chen C, Schreckenberger P, **Danziger L**. In Vitro Activity of Clarithromycin and its 14-Hydroxymetabolite alone and In Combination Against 23 Clinical Isolates of Legionella. 2nd Annual Conference on the Macrolides, Azolides and Streptogramins. Venice, Italy. January

1994. Abstract 139.

Pendland S, Piscitelli S, Schreckenberger P, **Danziger L**. In-vitro Activity of Metronidazole and its Hydroxymetabolite against Bacteroides Using the Checkerboard Method. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA. October 1993. Abstract 145.

Kanyok T, Jagannath C, Reddy V, **Danziger L**, Gangadharam P. The Invitro activity of L-Ofloxacin and Trospectomycin against MTB and MAC. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. October 1993. Abstract 1498.

Kanyok T, Jagannath C, Reddy V, **Danziger L**, Gangadharam P. The Invitro activity of Aminosidine (paromomycin) against a Multidrug Resistant Mycobacterium tuberculosis Infection in C57BL/6 Mice. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. October 1993. Abstract 290.

Fish D, Gotfried M, **Danziger L**, Rodvold K. Penetration of Clarithromycin into Lung Tissues at Steady State. 18th International Congress of Chemotherapy. Stockholm, Sweden. June 1993. Abstract 358.

Occhipinti D, Gubbins P, **Danziger L**. *Candida parapsilosis*: An Emerging Pathogen in the Urinary Tract. 18th International Congress of Chemotherapy. Stockholm, Sweden. June 1993. Abstract 107.

Gubbins P, Occhipinti D, Hoffman H, Schreckenberger P, **Danziger L**. Surveillance of Urinary Tract Fungal Isolates From a University Hospital: 1990-1992. 18th International Congress of Chemotherapy. Stockholm, Sweden. June 1993. Abstract 1075.

Kanyok, T. Reddy M, Jagannath C, **Danziger L**, Gangadaram P. Invitro antimycobacterial activity of paromomycin against MTB and MAC. 18th International Congress of Chemotherapy. Stockholm, Sweden. June 1993. Abstract 8.

Kanyok, T. Reddy M, Jagannath C, **Danziger L**, Gangadaram P. Invitro efficacy of paromomycin against MTB infection in C57BI/6 mice. 18th International Congress of Chemotherapy. Stockholm, Sweden. June 1993. Abstract 931.

Kanyok, T. Reddy M, Jagannath C, **Danziger L**, Gangadaram P. Invitro efficacy of paromomycin against MAC infection in C57BI/Bg^j/Bg^j mice. 18th International Congress of Chemotherapy. Stockholm, Sweden. June 1993. Abstract 932.

Kanyok T, Novak R, **Danziger L**. Results of a Randomized, Blinded Trial of Paromomycin vs Placebo for the Treatment of Cryptosporidium Diarrhea in AIDs Patients. IX International Conference on AIDs. Berlin, Germany. June 1993.

Occhipinti D, Piscitelli S, Hill C, Deyo K, **Danziger L**, Fisher J. Acetylation and Hydroxylation of Dapsone in Leprosy Patients: Relation to Toxicity. Clin Pharmacol Ther. pg. 158. February 1993. ASCPT (#94).

Piscitelli S, Cunningham F, **Danziger L**, Rodvold K, Fischer J. Multiple Dose Evaluation of a Single Dose of Ranitidine. American Society for Clinical Pharmacology and Therapeutics (ASCPT). Clin Pharmacol Ther. pg. 218, February 1993. Abstract 49.

- Weddle D, Cooksey J, **Danziger L**, Kirk G. An Interdisciplinary Community Based Primary Health Care Course for Health Professional Students. American Dietetics Association. New Orleans, LA. 1992.
- Occhipinti D, Gubbins P, **Danziger L**, Schreckenberger P. Incidence, Treatment, and Microbiologic Outcomes of Non-Albicans Fungal Urinary Tract Pathogens. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1992. Abstract 839.
- Fish D, **Danziger L**, Novak R, Hatoum H. Pharmacoeconomic evaluation of the Antimicrobial Therapy of Bacteremia. 9th Annual Meeting of the American College of Clinical Pharmacy. August 1992. Abstract 96.
- Piscitelli SC, **Danziger L**, Hill C, et al. Long Term Analysis of a Dapsone Compliance Program in Patients with Hansen's Disease. ACCP Winter Research and Practice Forum (#44). February 1992. *Pharmacotherapy*. 1991; 11:44.
- Gubbins P, Occhipinti D, Pitts G, **Danziger L**. A Five Year Retrospective Surveillance of the Treatment and Microbiologic Outcomes of Fungal Urine Cultures Positive for *Candida Albicans*. ACCP Winter Research and Practice Forum (#23). February 1992. *Pharmacotherapy*. 1991; 11:34.
- Piscitelli S, **Danziger L**, Hill C, West D, Fischer J. Long Term Analysis of Dapsone Compliance Program in Patients with Hansen's Disease. ACCP Winter Research and Practice Forum (#11); February 1992. *Pharmacotherapy*. 1991;11:32.
- Lewis R, Gubbins P, Fish D, **Danziger L**. Impact of Biotechnology Drugs on the Outcomes of Sepsis. 26th Annual ASHP Midyear Clinical Meeting. New Orleans, LA. December 1991. Abstract 230.
- Wilkes L, **Danziger L**, Shwed J, et al. Steady State Pharmacokinetics of Metronidazole and the hydroxymetabolite in the Critically Ill. 17th International Congress of Chemotherapy (ICC)., Berlin, Germany. June, 1991. Abstract 1711
- Shwed J, Cunningham F, **Danziger L**, Fischer J. Case Report: Tolerance of effect for ranitidine in a critically ill patient. *Pharmacotherapy*. 1991;11:104. Abstract 50.
- Shwed J, **Danziger L**, Rodvold K. Evaluation of Cefotetan for Safety and Efficacy in a Surgical Population. 24th Annual Midyear Clinical Meeting. Atlanta GA. 1989. Vol 24:110. Abstract 317.
- Cunningham F, Nanavaty M, Fischer J, **Danziger L**, Rodvold K, Bombeck CT. Pharmacokinetic/Pharmacodynamic model for nizatidine effect on basal Gastric Acid output. *Clin Pharmacol Ther*. 1989. 45:141.
- Demise J, **Danziger L**, Kirschenbaum G, Bertch K. Effect of Ceftazidime and Imipenem on Leukocyte function In-Vitro *Pharmacotherapy*. 1988; 8:123.
- Furmaga K, **Danziger L**, Rodvold K, Bombeck CT, Fischer J. Pharmacokinetic-Pharmacodynamics of two dosing regimens of Nizatidine, *Pharmacotherapy*. 1988; 8:131.
- Danziger, L**, Albumin. Clinical Use and Cost Effectiveness. 10th Clinical Congress ASPEN. Febuary

1986. Abstract 109-112.

Danziger L, Stellato T, Kosir M, Gordon N. Effects of hypoalbuminemia on morbidity and mortality. *Drug Intell Clin Pharm.* June 1987. 21

Danziger L, Creger R, Stellato T, Hau T. A randomized trial of gentamicin and clindamycin versus imipenem in serious infections. *Drug Intel Clin Pharm.* 1985. 19:455.

Creger R, Cowan R, **Danziger L**, Nearman H. Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients. *Drug Intel Clin Pharm.* 1985. 19:455. #132

Hau T, Stellato T, **Danziger L**. Prophylaxis of Infections in colon surgery. XV Kongress der Gesellschaft fir Chirurgie der DDR. Berlin, Germany. March 1985.

Danziger L, Stellato T, Gauderur M, Ferron J, Hau T. A prospective double-blind randomized study comparing moxalactam and tobramycin plus clindamycin in treatment of intraabdominal sepsis. *Drug Intel Clin Pharm.* 1984. 18:458, #184.

Danziger L. Case report of urinary retention secondary to disopyramide. *Am J Hosp Pharm.* 1978. 35:1302.